Document is current
Any future updates will be listed below
-
Authors
Belteki, Z. https://orcid.org/0000-0002-1619-444X
Ward, E. K.
Begum-Ali, J.
van den Boomen, C.
Bölte, S.
Buitelaar, J.
Charman, T.
Demurie, E.
Falck-Ytter, T.
Hunnius, S.
Johnson, M. H.
Jones, E. J. H.
Oosterling, I.
Pasco, G.
Pijl, M. K. J.
Radkowska, A.
Rudling, M.
Tomalski, P.
Warreyn, P.
Junge, C.
Haman, E.
-
Funding
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (814302)
Ministerie van Onderwijs, Cultuur en Wetenschap (024.001.003)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VI.Vidi.211.245)
National Science Centre of Poland (2012/07/B/HS6/01464)
Innovative Medicines Initiative 2 Joint Undertaking (No 777394)
- License Information
-
More Information
Article History
Accepted: 9 November 2024
First Online: 17 January 2025
Declarations
:
: Jan Buitelaar has been a consultant to / member of advisory board of / and/or speaker for Takeda, Roche, Medice, Angelini, Neuraxpharm, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Sven Bölte discloses that he has in the last 3 years acted as an author, consultant, or lecturer for Medice and LinusBio. He receives royalties for textbooks and diagnostic tools from Hogrefe, UTB, Ernst Reinhardt, Kohlhammer, and Liber. Bölte is partner NeuroSupportSolutions International AB. Tony Charman has served as a paid consultant to F. Hoffmann-La Roche Ltd. and Servier and receives royalties from Sage Publications and Guilford Publications.
: The authors declare no conflicts of interest.
